944154-87-4

Upstream product

• 183293-41-6 (S)-O-p-toluenesulfonyl-3-hydroxy-2-methylpropanal 
• 98-59-9 p-toluenesulfonyl chloride 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 501015-40-3 (2S,3S)-(+)-toluene-4-sulfonic acid 3-hydroxy-2-methylhex-5-enyl ester 
• 84341-89-9 (2S)-(+)-2-methyl-3-(toluene-4-sulfonyloxy)propionic acid methyl ester 
• 944154-95-4 (R)-4-benzyl-3-((2R,3S)-3-(tert-butyldimethylsilyloxy)-2-methylhex-5-enoyl) oxazolidin-2-one 
• 944154-86-3 (R)-4-benzyl-3-((2R,3S)-3-hydroxy-2-methylhex-5-enoyl)oxazolidin-2-one 
• 944154-96-5 (2S,3S)-3-[(tert-butyldimethylsilyl)oxy]-2-methylhex-5-en-1-ol 

Downstream Products

• 1436866-91-9 C₂₁H₃₄O₆SSi 

Relevant academic research and scientific papers

Modular total syntheses of mycolactone A/B and its [2H]-isotopologue

A modular total synthesis of mycolactone A/B, the exotoxin produced by Mycobacterium ulcerans, has been achieved through the orchestration of several Pd-catalyzed key steps. While this route leads to a mixture of the natural product and its C12 epimer (4:

STRUCTURAL VARIANTS OF MYCOLACTONES FOR USE IN MODULATING INFLAMMATION, IMMUNITY AND PAIN

The present invention is related to variants of mycolactones of formula (I), processes for the preparation thereof, pharmaceutical compositions thereof and their use in modulating inflammation, immunity and pain. Y-O-W (I), wherein Y and W are as defined in claim 1.

Structural variants of mycolactones for use in modulating inflammation, immunity and pain

The present invention is related to variants of mycolactones of formula (I), processes for the preparation thereof, pharmaceutical compositions thereof and their use in modulating inflammation, immunity and pain. ???????? Y-O-W?????(I) wherein Y and W are as defined in claim 1.

A diverted total synthesis of mycolactone analogues: An insight into buruli ulcer toxins

Mycolactones are complex macrolides responsible for a severe necrotizing skin disease called Buruli ulcer. Deciphering their functional interactions is of fundamental importance for the understanding, and ultimately, the control of this devastating mycobacterial infection. We report herein a diverted total synthesis approach of mycolactones analogues and provide the first insights into their structure-activity relationship based on cytopathic assays on L929 fibroblasts. The lowest concentration inducing a cytopathic effect was determined for selected analogues, allowing a clear picture to emerge by comparison with the natural toxins.

Stereoselective synthesis of an advanced seco ester intermediate as a precursor toward the synthesis of amphidinolides T1, T3, and T4

An efficient, convergent, and stereoselective synthesis of a very advanced intermediate toward the total synthesis of amphidinolides T1, T3, and T4 utilising Evan's aldol and alkylation reactions, oxy-Michael, cross metathesis, stereoselective Grignard ad

Synthesis of the C1-C12 fragment of amphidinolide T1

A synthesis of the C1-C12 fragment of amphidinolide T1 utilising Evans' aldol, oxy-Michael and cross metathesis reactions as the key steps is described.